Abstract
There are many reports suggesting the effectiveness of combination therapy of cytotoxic agents and immune checkpoint inhibitors in patients with non-small cell lung cancer. There have been some cases of long-term administration of pembrolizumab because good disease control of the patient can be maintained. We assessed the prognosis of patients who continued to be administer pembrolizumab at our institution for more than one year.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
